Inhibitors



bPiDI

Cat. No.: HY-152170 CAS No.: 525596-64-9 Molecular Formula: $C_{22}H_{34}I_{2}N_{2}$ Molecular Weight: 580.33 nAChR Target:

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

4°C, sealed storage, away from moisture Storage:

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (172.32 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.7232 mL	8.6158 mL	17.2316 mL
	5 mM	0.3446 mL	1.7232 mL	3.4463 mL
	10 mM	0.1723 mL	0.8616 mL	1.7232 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (8.62 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (8.62 mM); Clear solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 5 mg/mL (8.62 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with $\alpha 6\beta 2$ -containing nAChRs^[1].

REFERENCES

[1]. Thomas E Wooters, et al. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol. 2011, 163,2.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com